p53, c-erbB-2 expression and steroid hormone receptors in breast carcinoma: correlations with histopathological parameters

Objective: The aim of the study was to evaluate the p53 tumor suppressor gene, c-erbB-2 and steroid hormone receptor expression in breast carcinoma by immunohistochemistry and to correlate them with different histopathologic parameters.

Materials and methods: p53, c-erbB-2, steroid hormone receptors and their correlation with age, tumor size, histological grade, axillary lymph-node status, and menopausal status were investigated in 65 breast carcinoma cases. All markers were measured immunohistochemically on paraffin sections. Association between estrogen receptor (ER), progesterone receptor (PgR), p53 and c-erbB-2 expression and clinicopathologic variables were assessed by the chi-square test for qualitative parameters.

Results: c-erbB-2 staining was found in 35.3% of breast carcinomas and was associated with ductal subtype and age under 35 (p = 0.022, p = 0.003, respectively); p53 staining was seen in 27.6% of cases and was associated with high histological grade and postmenapausal status (p = 0.038, p = 0.002, respectively). Progesterone receptor expression was associated with positive axillary status (p = 0.003).

Conclusion: We concluded that expressions of c-erbB-2, p53, ER, and PgR may be used in the evaluation of breast carcinoma. Therefore the present study suggests that p53 expression is a marker of high histological grade in postmenopausal status, and that c-erbB-2 expression is associated with histologically ductal subtype.

Breast carcinoma; p53; c-erbB-2; Estrogen receptor; Progesterone receptor

[1] Haerslev T., Jaacobsen G.K., Zedeler K.: "Correlation of growth fraction by Ki-67 and proliferating cell nuclear antigen (PCNA) immunohistochemistry with histopathological parameters and prognosis in primary breast carcinomas". Breast Cancer Res Treat., 1996, 37, 101.

[2] Ellis G.K., Gown A.M.: "New applications of monoclonal antJbodies to the diagnosis and prognosis of breast cancer". Pathol. Annu., 1990, 25, 193.

[3] Caleffi M., Teague M.W., Jensen R.A., Vnenck Jones C.L.: "p53 gene mutations and steroid receptor status in breast cancer. Clinicopathologic correlations and prognostic assessment". Cancer, 1994, 73, 2147.

[4] Ho G.H., Calvano J.E., Bisogna M., Borgen P.I., Rosen P.P., Tan L.K. et al.: "In microdissected ductal carcinoma in situ. HER-2/neu amplification, but not p53 mutation, is associated with high nuclear grade and comedo histology". Cancer, 2000, 89, 2153.

[5] Bebenek M., Bar J.K., Harlozinska A., Sedlaczek P.: "Prospective studies of p53 and c-erbB-2 expression in relation to clinicopathological parameters of human ductal breast cancer in the second stage of clinical advancement". Anticancer Res., 1998, 18, 619.

[6] Bloom H.J.G., Richardson W.W.: "Histological grading and prognosis in breast cancer". Br. J. Cancer, 1957, 11, 3641.

[7] Ohsumi S., Kasahara M., Hayashi K.. Murakami M., Kuroda M., Miemoto H. et al.: "Cyto-biological analysis of the breast cancer" Fujita Gakuen Igakkashi (in Japanese), 1994, 18, 217.

[8] Ostrowsky J.L., Sawan A., Henry L.: "p53 expresssion in human breast cancer related to survival and prognostic factors: An immunohistochemical study". J. Pathol., 1991, 164, 75.

[9] Kesari A.L.. Chellam V.G., Nair P.P., Ahmed I., Madhavan J., Thomas P.A. et al.: "p53 tumor suppressor protein and tissue proliferative fraction in infiltrating duct carcinoma". J. Surg. Oneal., 1997, 65, 159.

[10] Dawkins H.J., Robbins P.O., Smith K.L., Sarna M., Harvey J.M., Sterrett G.F. et al.: "What's new in breast cancer'? Molecular perspectives of cancer development and the role of the oncogene c-erbB-2 in prognosis and disease". Pathol. Res. Pract., 1993, 189, 1233.

[11] Shi Y.F., Xie X., Zhao C.L., Ye F., Lu S.M ., Hor J.J. et al.: "Lack of mutation in tumour-suppressor gene p53 in gestational trophoblastic tumours". Br. J. Cancer, 1996, 73, 1216.

[12] Takikawa Y., Noguchi M., Kitagawa H., Thomas M.: "Immmunohistochemical detection of p53 and c-erbB-2 proteins: prognostic significance in operable breast cancer". Breast Cancer,1994, 1, 17.

[13] Pinder S.E., Wencyk P.M., Naylor H.E., Bell J.A., Elston C.W., Robertson J.F.R. et al.: "The assesment of multiple variables on breast carcinoma fine needle aspiration (FNA) cytology specimens: metod, preliminary results and prognostic associations" Cytopathology, 1995, 6, 316.

[14] Yokota T., Imamura M., Teshima S., Suzuki H., Tezuka F., Kikuchi S. et al.: "c-erbB-2, p53 protein expression and steroid hormone receptors in breast carcinomas: an immunohistochemical study" Anticancer Res., 1999, 19, 4007.

[15] Berry D.A., Muss H.B., Thor A.O., Dressler L., Liu E.T., Broadwater G. et al.: "HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer". J. Clin. Oneal., 2000, 18, 3471 .

[16] Chung M., Chang H.R., Bland K.1. et al.: "Younger women with breast carcinoma have a poorer prognosis than older women". Cancer, 1996, 77, 97.

[17] Winchester D.P., Osteen R.T., Menck H.R.: "The National Cancer Data Base report on breast carcinoma characteristics and outcome in relation to age". Cancer, 1996, 7, 1838.

[18] Barbareschi M., Leonard心，Mauri F.A., Serio G., Dalla Palma P: "p53 and c-erbB-2 protein expression in breast carcinomas. An irnmunohistochernical study including correlations with receptor status, proliferation markers, and clinical stage in human breast cancer". Am. J. Clin. Pathol., 1992, 98, 408.

[19] Rudas M., Neumayer R., Gnant M.F., Mittelbock M., Jakesz R., Reiner A.: "p53 protein expression, cell proliferation and steroid hormone receptors in ductal and lobular in situ carcinomas of the breast". Eur. J. Cancer, 1997, 33, 39.

[20] Barnes D.M., Dublin E.A., Fisher CJ., Levison D.A., Millis R.R.: "Irnrnunohistochemical detection of p53 protein in mammary carcinoma: an important new independent indicator of prognosis?" Hum. Pathol., 1993, 24. 469.

[21] Cattoretti G., Rilke F., Andreola S., D'Amato L., Delia D.: "p53 expression in breast cancer". Int. J. Cancer, 1988, 41, 178.

[22] Bhargava V., Thor A., Deng G., Ljung B.M., Moore D.H. 2nd Waldman F. et al: "The assodation of p53 immunopositivity with tumor proliferation and other prognostic indicators in breast cancer". Mod. Pathol., 1994, 7, 361.

[23] Quenel N., Wafflart J., Bonichon F., De Mascarel I., Trojani M., Durand M. et al.: "The prognostic value of c-erbB2 in primary breast carcinomas: a study on 942 cases". Breast Cancer Res. Treat., 1995, 35, 283.

[24] Korkolis D., Ardavanis A., Yotis J., Kyroudi A., Gorgoulis V., Kittas C.: "HER-2/neu overexpression in breast cancer: an immunohistochemical study including correlations with clinicopathologic parameters, p53 oncoprotein and cathepsin-D". Anticancer Res., 2001, 21, 2207.

[25] Aryandono T., Harijadi, Ghozali A.: "Correlation of clinical, pathological status, hormone receptor and c-erbB-2 oncoprotein in breast cancer patients". Gan To Kagaku Ryoho, 2000, 27, 600.

[26] Tsutsui S., Ohno S., Murakami S., Hachitanda Y., Oda S.: "Prognostic value of c-erbB2 expression in breast cancer". J. Surg Oneal., 2002, 79, 216.